Search

Your search keyword '"Juliet C. Gray"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Juliet C. Gray" Remove constraint Author: "Juliet C. Gray"
49 results on '"Juliet C. Gray"'

Search Results

1. Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro

2. Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma

3. Immune characterization of pre-clinical murine models of neuroblastoma

4. Immune reconstitution in children following chemotherapy for acute leukemia

5. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

6. Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

8. Figure S1 from Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

9. Data from Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

10. Tri-lineage differentiation potential of osteosarcoma cell lines and human bone marrow stromal cells from different anatomical locations

11. National advisory panels for childhood cancer in the United Kingdom: An evaluation of current practice and a best practice statement for the future

12. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments

13. Methodological advances in the discovery of novel neuroblastoma therapeutics

14. DIPG harbour alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition

15. Prevalence of metachronous contralateral mature ovarian teratoma: A systematic review

16. The Role of Pre-Clinical 3-Dimensional Models of Osteosarcoma

17. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

18. Improving paediatric antimicrobial stewardship in hospital-based settings: why, where and how?

19. PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?

20. PEPtalk2:results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer

21. Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy

22. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

23. G359(P) Characterising the disease presentations of lch over 10 yr at a uk ptc

24. Immunotherapy for Pediatric Malignancies

25. Mutations in the transcriptional repressor REST predispose to Wilms tumor

26. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy

27. Osteonecrosis following treatment for childhood acute lymphoblastic leukaemia: The Southampton Children's Hospital experience

28. Overview of Monoclonal Antibody Therapies

29. Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood

30. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial

31. Hypercalcaemia secondary to ectopic parathyroid hormone expression in an adolescent with metastatic alveolar rhabdomyosarcoma

32. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

33. PO-413 Immune modulating properties of cyclophosphamide synergise with immunotherapy in preclinical models of neuroblastoma

34. Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls

35. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies

36. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation

37. Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms

38. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model

39. Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial)

40. Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma

41. Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO

42. Erratum: Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumor

43. Abstract A032: Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients

44. Narcolepsy with cataplexy as presenting symptom of occult neuroblastoma

45. Hepatoblastoma in a child with a paternally-inherited ABCC8 mutation and mosaic paternal uniparental disomy 11p causing focal congenital hyperinsulinism

46. PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy

47. Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients

48. Therapeutic potential of immunostimulatory monoclonal antibodies

Catalog

Books, media, physical & digital resources